Acasti Pharma (ACST) Competitors $3.37 -0.03 (-0.88%) (As of 10/25/2024) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends ACST vs. CRDF, IMUX, ACRS, PDSB, MCRB, RANI, ANRO, IPSC, OPTN, and IVVDShould you be buying Acasti Pharma stock or one of its competitors? The main competitors of Acasti Pharma include Cardiff Oncology (CRDF), Immunic (IMUX), Aclaris Therapeutics (ACRS), PDS Biotechnology (PDSB), Seres Therapeutics (MCRB), Rani Therapeutics (RANI), Alto Neuroscience (ANRO), Century Therapeutics (IPSC), OptiNose (OPTN), and Invivyd (IVVD). These companies are all part of the "pharmaceutical products" industry. Acasti Pharma vs. Cardiff Oncology Immunic Aclaris Therapeutics PDS Biotechnology Seres Therapeutics Rani Therapeutics Alto Neuroscience Century Therapeutics OptiNose Invivyd Acasti Pharma (NASDAQ:ACST) and Cardiff Oncology (NASDAQ:CRDF) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, dividends, media sentiment, valuation, institutional ownership, profitability, analyst recommendations and community ranking. Does the MarketBeat Community prefer ACST or CRDF? Acasti Pharma received 274 more outperform votes than Cardiff Oncology when rated by MarketBeat users. Likewise, 70.65% of users gave Acasti Pharma an outperform vote while only 62.90% of users gave Cardiff Oncology an outperform vote. CompanyUnderperformOutperformAcasti PharmaOutperform Votes31370.65% Underperform Votes13029.35% Cardiff OncologyOutperform Votes3962.90% Underperform Votes2337.10% Does the media refer more to ACST or CRDF? In the previous week, Acasti Pharma and Acasti Pharma both had 2 articles in the media. Cardiff Oncology's average media sentiment score of 0.97 beat Acasti Pharma's score of 0.24 indicating that Cardiff Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acasti Pharma 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Cardiff Oncology 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do insiders & institutionals believe in ACST or CRDF? 6.1% of Acasti Pharma shares are owned by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are owned by institutional investors. 13.5% of Acasti Pharma shares are owned by company insiders. Comparatively, 7.8% of Cardiff Oncology shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts recommend ACST or CRDF? Acasti Pharma presently has a consensus target price of $10.00, suggesting a potential upside of 196.74%. Cardiff Oncology has a consensus target price of $9.67, suggesting a potential upside of 201.61%. Given Cardiff Oncology's higher possible upside, analysts clearly believe Cardiff Oncology is more favorable than Acasti Pharma.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Acasti Pharma 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiff Oncology 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher earnings and valuation, ACST or CRDF? Acasti Pharma has higher earnings, but lower revenue than Cardiff Oncology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Acasti Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAcasti PharmaN/AN/A-$12.85M-$1.44-2.34Cardiff Oncology$665K224.35-$41.44M-$0.91-3.52 Which has more volatility & risk, ACST or CRDF? Acasti Pharma has a beta of 1.52, indicating that its share price is 52% more volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.93, indicating that its share price is 93% more volatile than the S&P 500. Is ACST or CRDF more profitable? Acasti Pharma has a net margin of 0.00% compared to Cardiff Oncology's net margin of -6,143.91%. Acasti Pharma's return on equity of -13.61% beat Cardiff Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Acasti PharmaN/A -13.61% -11.56% Cardiff Oncology -6,143.91%-62.65%-52.69% SummaryAcasti Pharma beats Cardiff Oncology on 8 of the 15 factors compared between the two stocks. Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here Get Acasti Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ACST and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ACST vs. The Competition Export to ExcelMetricAcasti PharmaPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$31.68M$7.03B$5.40B$8.53BDividend YieldN/A7.96%5.13%4.14%P/E Ratio-2.969.93115.5615.18Price / SalesN/A381.421,484.3492.77Price / CashN/A47.3439.6634.07Price / Book0.515.324.665.02Net Income-$12.85M$153.56M$119.06M$225.46M7 Day PerformanceN/A0.11%0.80%0.37%1 Month Performance10.49%15.22%5.65%3.57%1 Year Performance44.02%41.14%36.76%29.44% Acasti Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ACSTAcasti Pharma2.6154 of 5 stars$3.37-0.9%$10.00+196.7%+39.8%$31.68MN/A-2.9632CRDFCardiff Oncology1.5192 of 5 stars$2.83+3.7%$9.67+241.6%+205.2%$126.57M$665,000.00-3.1120Upcoming EarningsShort Interest ↑News CoverageIMUXImmunic2.5679 of 5 stars$1.39+0.7%$11.20+705.8%+14.4%$125.21MN/A-0.9370News CoverageACRSAclaris Therapeutics3.3062 of 5 stars$1.69+31.0%$9.00+432.5%-58.9%$120.44M$32.02M-2.0686Upcoming EarningsPositive NewsHigh Trading VolumePDSBPDS Biotechnology0.8486 of 5 stars$3.12+0.3%$14.25+356.7%-23.4%$120.03MN/A-2.5620Analyst UpgradeMCRBSeres Therapeutics3.8449 of 5 stars$0.70-1.4%$5.08+621.1%-42.9%$119.97M$126.32M-0.60233Upcoming EarningsGap DownRANIRani Therapeutics3.1546 of 5 stars$2.34-2.1%$11.71+400.6%+20.9%$117.98M$2.72M-1.98110Gap UpANROAlto Neuroscience2.3264 of 5 stars$4.37+5.8%$24.40+458.4%N/A$117.48M$210,000.000.00N/AHigh Trading VolumeIPSCCentury Therapeutics1.768 of 5 stars$1.39-4.8%$12.75+817.3%-15.4%$117.46M$2.04M-0.68170Positive NewsOPTNOptiNose3.411 of 5 stars$0.77-2.5%$4.00+418.5%-45.7%$116.31M$70.99M-2.14190Gap DownIVVDInvivyd2.4769 of 5 stars$0.97-1.0%$11.33+1,063.5%-37.9%$116.23M$2.26M-0.54100Analyst ForecastNews Coverage Related Companies and Tools Related Companies CRDF Alternatives IMUX Alternatives ACRS Alternatives PDSB Alternatives MCRB Alternatives RANI Alternatives ANRO Alternatives IPSC Alternatives OPTN Alternatives IVVD Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:ACST) was last updated on 11/2/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredEx WH Advisor Who Predicted Biden Leaving Race Makes Startling New PredictionFormer advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredMarket "Famine" ComingMarket Wizard Larry Benedict accurately predicted that all indexes would be negative in 2022... He predicte...Opportunistic Trader | SponsoredMusk Says ‘Dollar Will Be Worth Nothing…’Elon Musk just issued an urgent warning… It's no secret that Musk is able to move markets with his words…Crypto 101 Media | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredNvidia warning urgentI thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredNothing can stop this gold rallyAfter what's felt like nearly a decade of disappointing gains, gold is stronger than ever and continues to hit...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Acasti Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Acasti Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
